Gene · 8784
Papers4,557
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
961 to 980 of 4,557
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The angiogenic genes predict prognosis and immune characteristics in esophageal squamous cell carcinoma: Evidence from multi-omics and experimental verification. | Front Oncol | 2022 | 36158681 | PubTator, text mining | PubMed |
| Decreased GZMB, NRP1, ITPR1, and SERPINB9 Transcripts Lead to Reduced Regulatory T Cells Suppressive Capacity in Generalized Vitiligo Patients. | J Immunol Res | 2022 | 36157881 | PubTator, text mining | PubMed |
| Identification of Novel Immunologic Checkpoint Gene Prognostic Markers for Ovarian Cancer. | J Oncol | 2022 | 36157232 | PubTator, text mining | PubMed |
| Recent developments in application of single-cell RNA sequencing in the tumour immune microenvironment and cancer therapy. | Mil Med Res | 2022 | 36154923 | PubTator, text mining | PubMed |
| Microenvironment components and spatially resolved single-cell transcriptome atlas of breast cancer metastatic axillary lymph nodes. | Acta Biochim Biophys Sin (Shanghai) | 2022 | 36148946 | PubTator, text mining | PubMed |
| Traumatic Brain Injury Induces a Differential Immune Response in Polytrauma Patients; Prospective Analysis of CD69 Expression on T Cells and Platelet Expansion. | J Clin Med | 2022 | 36142962 | PubTator, text mining | PubMed |
| Finding the Right Heavy Chains for Immunostimulatory Antibodies. | Int J Mol Sci | 2022 | 36142278 | PubTator, text mining | PubMed |
| The Interplay of Tumor Vessels and Immune Cells Affects Immunotherapy of Glioblastoma. | Biomedicines | 2022 | 36140392 | PubTator, text mining | PubMed |
| Alphaviruses in Immunotherapy and Anticancer Therapy. | Biomedicines | 2022 | 36140364 | PubTator, text mining | PubMed |
| Leveraging the Dynamic Immune Environment Triad in Patients with Breast Cancer: Tumour, Lymph Node, and Peripheral Blood. | Cancers (Basel) | 2022 | 36139665 | PubTator, text mining | PubMed |
| DNA Methylation in Regulatory T Cell Differentiation and Function: Challenges and Opportunities. | Biomolecules | 2022 | 36139121 | PubTator, text mining | PubMed |
| Feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE). | Support Care Cancer | 2022 | 36136246 | PubTator, text mining | PubMed |
| Deciphering the endometrial immune landscape of RIF during the window of implantation from cellular senescence by integrated bioinformatics analysis and machine learning. | Front Immunol | 2022 | 36131919 | PubTator, text mining | PubMed |
| An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment. | Cancer Commun (Lond) | 2022 | 36129048 | PubTator, text mining | PubMed |
| Stress-Mediated Attenuation of Translation Undermines T-cell Activity in Cancer. | Cancer Res | 2022 | 36126165 | PubTator, text mining | PubMed |
| Advanced Acral Melanoma Therapies: Current Status and Future Directions. | Curr Treat Options Oncol | 2022 | 36125617 | PubTator, text mining | PubMed |
| SLC22A8: An indicator for tumor immune microenvironment and prognosis of ccRCC from a comprehensive analysis of bioinformatics. | Medicine (Baltimore) | 2022 | 36123895 | PubTator, text mining | PubMed |
| CAR-T cell potency: from structural elements to vector backbone components. | Biomark Res | 2022 | 36123710 | PubTator, text mining | PubMed |
| RAB6B is a potential prognostic marker and correlated with the remolding of tumor immune microenvironment in hepatocellular carcinoma. | Front Pharmacol | 2022 | 36120364 | PubTator, text mining | PubMed |
| Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities. | Front Oncol | 2022 | 36119533 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8784/papers?page=49